Trials / Completed
CompletedNCT05844111
A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417
A Phase 1 Study To Investigate The Absorption, Metabolism, and Excretion of [14C]-BGB-11417 Following Single Oral Dose Administration in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to determine the mass balance, routes of elimination, and pharmacokinetics of \[14C\]-BGB-11417 in healthy male participants along with determining the concentrations of radioactivity in plasma, fecal and urinary elimination of total radioactivity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-BGB-11417 | A single oral dose of liquid formulation |
Timeline
- Start date
- 2023-05-22
- Primary completion
- 2023-06-18
- Completion
- 2023-06-18
- First posted
- 2023-05-06
- Last updated
- 2025-04-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05844111. Inclusion in this directory is not an endorsement.